Study at a glance
What was studied?
Researchers asked whether vitamin D changes how the body uses sugar and fat for energy. They studied people, animals and cells. Some human studies gave vitamin D or a comparison treatment. Others compared people with different vitamin D blood results.
What did the studies find?
One trial found an improvement in a laboratory test of insulin response. Other trials did not show the same benefit. A small study found a change in the liver’s response without a clear improvement in overall glucose removal. Cell measurements also differed between tissues.
What does this mean?
Using more oxygen, responding to insulin and switching between sugar and fat are different measurements. An improvement in one does not prove an improvement in all three. Body fat can also influence the amount of vitamin D measured in blood.
What are the limits?
Several studies were small or lost participants before the final measurements. Cell and animal experiments cannot establish a benefit from supplements in people. These studies do not establish a personal dose, a blood target or a reliable way to improve fuel switching.
Read the full article below ↓Vitamin D research connects fuel use, insulin responses and inflammatory signalling, but these are different scientific questions. This review compares nine research programmes to ask what was actually measured, where findings agree and where they diverge. It separates direct measurements of glucose and fat use from laboratory markers that may be relevant without measuring the same outcome. For the shorter account, read Vitamin D, Fuel Switching and Insulin Sensitivity: Study Summary.
What counts as fuel switching?
Metabolic flexibility means changing fuel use when conditions change, such as moving from fasting to feeding. Measuring fat oxidation once is different from measuring how it changes during a defined challenge. Likewise, the amount of glucose entering tissues need not equal the amount immediately burned for energy: some can be stored. The physiological overview Vitamin D and Metabolic Flexibility introduces this coordination; the studies below test particular parts of it.
Mitochondrial efficiency has a narrower meaning than simply greater oxygen consumption. Adenosine triphosphate, or ATP, is a molecule that transfers usable energy within cells. Oxygen use can reflect energy demand, ATP-linked activity or energy lost through other processes. Establishing efficiency requires an appropriate relationship between useful output and energetic input. The background on Vitamin D and Mitochondrial Function helps locate these measurements, but an oxygen-use result alone cannot establish that supplements make human mitochondria more efficient.
The evidence also uses different exposures. A blood measurement of 25-hydroxyvitamin D describes circulating vitamin D status. Giving vitamin D3 is an intervention. Giving calcitriol, the active hormone, directly to cultured cells is another experiment. Removing or increasing the vitamin D receptor in an animal changes the signalling machinery itself. These designs can inform one another, but they cannot be treated as equivalent doses of the same treatment.
Whole-body oxidation: a direct measurement with a limited question
Zhang and colleagues studied 69 young, healthy, non-obese adults in a metabolic chamber. Oxygen consumption and carbon dioxide production were used to estimate energy expenditure and fuel oxidation during structured activities and meals. Across three vitamin D status groups, total carbohydrate oxidation medians were 0.139, 0.153 and 0.158 grams per minute; the overall comparison had P = 0.198. Fat oxidation medians were 0.047, 0.041 and 0.044 grams per minute, with P = 0.669. The study therefore did not detect clear group differences in those outcomes.
These are useful whole-body measurements, but the design was observational. Participants were not randomly assigned to vitamin D status, and the smallest status group contained only 14 people. Seasonal differences, fitness and other characteristics could affect interpretation. The paper’s causal-sounding title should not be taken as proof that vitamin D cannot affect metabolism. Nor did the reported comparison establish a predefined change in flexibility between fasting and feeding.
A separate report by Pathak and colleagues described a positive association between vitamin D status and post-glucose metabolic responses. Here it is used only as qualitative abstract-level background because the complete material results were not available for appraisal. It prevents a misleading claim that all human association studies are negative, but it does not establish a supplementation effect or support a detailed numerical comparison.
A kidney-disease trial measured substrate handling
Petchey and colleagues randomly assigned 28 adults with stage 3 to 4 chronic kidney disease to vitamin D3 at 2,000 IU daily or placebo for six months. This was a research regimen, not a personal dose recommendation. Twenty-five contributed the analysed outcomes: 11 in the vitamin D group and 14 in the placebo group. The investigators combined an insulin clamp with indirect calorimetry. A clamp assesses glucose handling under controlled insulin and glucose conditions, while calorimetry estimates fuel oxidation. This combination addressed relative substrate use more directly than a resting cell oxygen measurement.
There was no clear between-group improvement in glucose disposal or fuel handling. An improvement in oxidative glucose disposal within the vitamin D group was not sufficient to establish a treatment effect: the relevant question is whether its change differed from the placebo group’s change. Most participants started with relatively sufficient vitamin D status, and the trial was small. Its renal-disease setting and missing outcomes limit generalisation to people with severe deficiency or without kidney disease.
The trial does not prove equivalence between treatment and placebo, nor does it establish that every form of metabolic challenge is unaffected. It supplies a restricted clinical counterweight to claims based only on cell mechanisms. The broad coordination of intake, storage and expenditure is explained in Vitamin D and Energy Regulation; this trial measured selected components rather than that entire system.
Cell respiration and muscle lipid findings answer different questions
Calton and colleagues studied blood immune cells from 38 adults. Those with lower vitamin D status had higher adjusted basal and ATP-linked oxygen consumption. This direction alone challenges the assumption that lower vitamin D must always mean lower respiration. Yet the study found no clear adjusted differences in several other measurements, including coupling, maximal respiration and the composite bioenergetic health index. ATP-linked oxygen consumption was not a direct measurement of ATP production efficiency.
The study also identified an association between the bioenergetic index and an estimate of insulin sensitivity. This was a cross-sectional association in a small sample of mixed immune cells, with possible platelet contamination and residual confounding. It was not a treatment experiment, a muscle test or a measurement of fuel switching. A sensitivity analysis addressing platelet contamination was considered in the source appraisal, but it does not remove all limitations of the design.
Chang and Kim investigated rats and cultured muscle cells within one research programme. In the cell experiments, active vitamin D reduced lipid accumulation and changed markers associated with cellular energy signalling. Some ATP and mitochondrial measurements also changed. The rat and cell findings support biological plausibility, but the study did not directly measure fatty-acid oxidation or a dynamic switch between fuels. Changes in the AMPK and SIRT1 signalling systems did not by themselves establish that either pathway was necessary for the lipid result.
This matters for interpreting Vitamin D and Lipid Metabolism. Less lipid stored inside a cell can arise through several processes; it is not automatically evidence of greater fat burning. The experimental exposures, multiple outcomes and animal-to-human differences further limit translation. The rat and cell components are counted together here, not presented as two independent confirmations of a human benefit.
Insulin sensitivity: a positive trial and an uncertain comparison
Lemieux and colleagues randomly assigned 96 adults at high risk of diabetes or with newly diagnosed diabetes to vitamin D3 at 5,000 IU daily or placebo for six months. These were research regimens in selected populations, not personal dose recommendations. There were 48 participants in each group at allocation and clamp outcomes for 47 and 43 respectively. The trial found improved clamp-based insulin sensitivity relative to placebo: the treatment-by-time comparison for the primary glucose-disposal measure had P = 0.009. The reported change in the glucose-disposal measure was +0.92 mg/kg/min in the vitamin D group (95% confidence interval 0.24 to 1.59), compared with −0.03 mg/kg/min in the placebo group (−0.73 to 0.67). These are separate arm changes and intervals, not a confidence interval for their difference. A measure adjusted for insulin concentration also favoured treatment, with P = 0.031.
The positive finding should remain visible. However, other estimates based on fasting or oral-glucose measurements, and the reported glycaemic outcomes, did not show clear treatment effects. The intended recruitment of 130 participants was not reached. Statistical analyses used transformed values for relevant outcomes, while some displays used original units. Exploratory subgroups cannot establish who reliably responds. The study measured insulin sensitivity, not direct fuel switching or prevention of diabetes.
Cefalo and colleagues studied vitamin D3 during a three-month calorie-restricted diet. Eighteen participants were analysed, nine per group. Insulin sensitivity improved from baseline in the vitamin D arm, but the group-by-time comparison was not significant, at P = 0.16. Calling this an established randomised benefit would confuse a within-group change with the treatment comparison. The participant flow also contains an unresolved discrepancy: 36 are described as randomised, but the allocation boxes total 33. This review does not invent an explanation for the missing three.
Substantial attrition, a small completer analysis and the shared dietary intervention make the Cefalo result uncertain. An analysis based on achieved vitamin D status does not establish an optimal blood concentration because those categories were not independently randomised. These contrasts show why Vitamin D and Insulin Signalling needs to be distinguished from claims about a reliable supplement response.
The primary insulin paper from the Mousa trial reports a null result. Its complete principal tables were not available for this review, so that result is retained only as explicitly limited qualitative background. It is the same underlying trial as the fully appraised inflammatory report discussed below, not an additional independent trial. Together, the positive, null and uncertain findings prevent either a universal benefit claim or a universal no-effect claim.
Liver responses do not establish a whole-body mechanism
Lontchi-Yimagou and colleagues combined a small human trial with a separate mouse experiment. Nineteen insulin-resistant adults with overweight or obesity and low starting vitamin D status were allocated to vitamin D3 or placebo, 11 and eight respectively. The six-month programme used staged vitamin D status targets; it did not establish an optimal target for routine care. Tracer measurements during clamps distinguished suppression of glucose production by the liver from overall glucose disposal in other tissues. Hepatic insulin responses improved without a clear overall disposal advantage.
The distinction is central to Vitamin D and Glucose Homeostasis: reducing glucose released by the liver is different from increasing its removal elsewhere. The human results did not measure a whole-body switch from glucose to fat. Several adipose-tissue marker changes were mainly comparisons within the supplemented group over time. They cannot establish that reduced inflammation mediated a randomised improvement in people.
The mouse receptor-deletion experiment supplied a mechanistic comparison, but genetic deletion is not ordinary nutritional supplementation. Most peripheral measurements were unchanged, although a subcutaneous fat uptake result differed, so a claim that all peripheral tissues were unaffected would also be inaccurate. Small human groups, later losses and multiple outcomes make this an exploratory programme rather than a definitive explanation of clinical response.
Inflammation and adiposity constrain the interpretation
Mousa and colleagues randomly assigned 65 adults with overweight or obesity and low vitamin D status; 54 completed the 16-week inflammatory analysis. Despite a substantial rise in blood vitamin D in the treated group, measured circulating inflammatory markers and immune-cell nuclear factor kappa-B activity did not show a net improvement. Nuclear factor kappa-B is a signalling regulator involved in inflammatory responses. This was a secondary-outcome analysis in otherwise relatively healthy participants with limited baseline inflammation.
The result therefore does not settle every tissue or disease context, but it directly qualifies an assumption that raising vitamin D automatically reduces metabolic inflammation. Circulating markers are not interchangeable with adipose tissue measurements. The physiological setting described in Vitamin D and Chronic Inflammation is broader than the endpoints in this trial; a plausible connection between inflammation and metabolism does not establish treatment mediation.
Vimaleswaran and colleagues examined causal direction using genetic variants across 21 cohorts, with up to 42,024 participants. Their Mendelian randomisation analysis used inherited variants as instruments for body mass index and vitamin D status. A genetically predicted 10% higher body mass index was associated with approximately 4.2% lower circulating vitamin D, with a 95% confidence interval from 1.3% to 7.1% lower. The reverse analysis did not provide comparable evidence that lower vitamin D raised body mass index.
This supports the possibility that adiposity contributes to low vitamin D measurements, rather than every association showing that low vitamin D caused adiposity. It depends on genetic-instrument assumptions and cannot exclude small or nonlinear effects, including effects in severely deficient groups. The larger follow-up dataset overlapped eight of the original cohorts, so it is not wholly independent replication. Neither analysis measured fuel switching directly.
Opposing receptor-model findings also remain relevant. Kang and colleagues and Wong and colleagues reported contexts in which receptor-related signalling was associated with adverse metabolic features. These reports are used here only as qualitative abstract-level background because material figures or supplementary evidence were not fully appraised. They do not supply numerical comparisons or additional qualified study counts. They reinforce the need to distinguish the receptor manipulation, tissue and experimental setting from an ordinary oral supplement.
What the combined evidence establishes
The strongest interpretation follows the measurement. Whole-body oxidation studies test fuel use; a clamp tests insulin-related glucose handling; immune-cell respiration tests one cellular compartment; and genetic studies can test a proposed causal direction under specific assumptions. Agreement across these designs can strengthen a hypothesis, but disagreement cannot be removed by calling every outcome metabolic flexibility.
These selected studies support context-dependent interactions between vitamin D biology and metabolic regulation. They include a positive clinical clamp result, restricted clinical null findings, uncertain small-trial comparisons and plausible cellular mechanisms. They do not establish a dependable supplement-induced improvement in glucose-to-fat switching, a universal increase in mitochondrial efficiency, or a personal dose or blood target. The unresolved translation is the link between a particular molecular or laboratory change and a sustained, meaningful metabolic benefit in people.
Source access and scope
This is a selected comparative review, not a pooled estimate or a claim to cover every vitamin D and metabolism study. Principal papers and the material tables and figures supporting the selected claims were assessed, with specific limits. Petchey’s complete scientific narrative and tables were available in an author-uploaded version, but graphical images were unavailable; no graph-derived estimate is used. Its 2013 erratum adds author Emma L. Duncan and does not supply a new efficacy result. Lemieux’s accepted manuscript was inspected, including its tables and figures.
For Lontchi-Yimagou, supplementary figure panels were not usable, and claims depending on them are excluded. No uninspected supplementary-only results are used for Chang, Vimaleswaran or other core reports. Pathak, the primary Mousa insulin report, Kang and Wong remain explicitly limited qualitative background. Publication identity and indexed correction records were checked on 4 November 2026; that check is not a guarantee that every notice in every database was found.
Sources
Related reading
A High Dose, Not Low Dose, of Vitamin D Ameliorates Insulin Resistance in Saudi Women
The aim of this study was to examine the effect of low and high doses of a vitamin D supplement on the serum levels of 25(OH)D3 and insulin resistance.
Original paper ↗Read more →Analysis of Association between Vitamin D Deficiency and Insulin Resistance
Recent evidence revealed extra skeleton activity of vitamin D, including prevention from cardiometabolic diseases and cancer development as well as anti-inflammatory properties.
Original paper ↗Read more →Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium
Future well-designed randomized controlled trials are required to define their long-term efficacy, safety, and role in personalized metabolic management.
Original paper ↗Read more →Effects of vitamin D on insulin resistance and myosteatosis in diet-induced obese mice
On this basis, this study aimed to evaluate the effect of vitamin D supplementation in a murine model of diet-induced insulin resistance with particular attention to the effects evoked on the skeletal muscle.
Original paper ↗Read more →Evaluating the Role of Vitamin D in Prediabetes Management, Insights from RCTs in the MENA Region: A Comprehensive Systematic Review
The association between vitamin D deficiency and prediabetes has been extensively investigated, yet the findings remain inconsistent, with limited data available on the MENA region.
Original paper ↗Read more →Hypothesized pathways for the association of vitamin D status and insulin sensitivity with resting energy expenditure: a cross sectional mediation analysis in Australian adults of European ancestry
The role of vitamin D in human energy expenditure requires confirmation.
Original paper ↗Read more →Insulin Requirement for Gestational Diabetes Control Is Related to Higher Vitamin D Levels up to 1 Year Postpartum: A Prospective Cohort Study
The aim of this study is to analyze vitamin D status evolution in a population of pregnant women with and without GDM.
Original paper ↗Read more →Low total and free triiodothyronine levels are associated with insulin resistance in non-diabetic individuals
This study examined associations of thyroid hormone levels and insulin resistance (IR) in non-diabetic individuals.
Original paper ↗Read more →Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice
Recent evidence has revealed anti-inflammatory properties of vitamin D as well as extra-skeletal activity.
Original paper ↗Read more →Metabolic Determinants of PCSK9 Regulation in Women with Polycystic Ovary Syndrome: The Role of Insulin Resistance, Obesity, and Tobacco Smoke Exposure
The aim of this study was to examine associations involving serum proprotein convertase subtilisin/kexin type 9 (PCSK9) in metabolic disturbances observed in women with polycystic ovary syndrome (PCOS), with particular emphasis on the potential impact of tobacco smoke exposure.
Original paper ↗Read more →No Association between 25-Hydroxyvitamin D and Insulin Resistance or Thyroid Hormone Concentrations in a Romanian Observational Study
Background and objectives: Vitamin D is involved in insulin resistance through genomic and non-genomic mechanisms.
Original paper ↗Read more →Risk of Insulin Resistance and Metabolic Syndrome in Women with Hyperandrogenemia: A Comparison between PCOS Phenotypes and Beyond
We compared four different PCOS phenotypes according to the Rotterdam criteria with women who exhibit only one Rotterdam criterion and with healthy controls.
Original paper ↗Read more →Serum and supplemental vitamin D levels and insulin resistance in T2DM populations: a meta-analysis and systematic review
In our current meta-analysis, there are 18 RCTs and 20 observational studies including 1243 and 11,063 participants respectively.
Original paper ↗Read more →Systematic thyroid screening in myotonic dystrophy: link between thyroid volume and insulin resistance
The aim of this study was to determine the prevalence and the causes of US thyroid abnormalities in DM1.
Original paper ↗Read more →The Effect of Puberty on Interaction between Vitamin D Status and Insulin Resistance in Obese Asian-Indian Children
To study the effect of puberty on the relationship between serum 25-hydroxyvitamin D (25(OH)D) and parameters of insulin kinetics in obese Asian-Indian children.
Original paper ↗Read more →The Relationship of Serum 25-Hydroxyvitamin D and Insulin Resistance among Nondiabetic Canadians: A Longitudinal Analysis of Participants of a Preventive Health Program
In the present study we examined whether temporal improvements in vitamin D status, measured as serum 25-hydroxyvitamin D [25(OH)D], reduce the risk of insulin resistance among individuals without T2D.
Original paper ↗Read more →The Role of Vitamin D Oral Supplementation in Insulin Resistance in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the effect of vitamin D supplementation (alone or with co-supplementation) on insulin resistance in patients with polycystic ovary syndrome (PCOS).
Original paper ↗Read more →Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells
The purpose of present study is to investigate a role of vitamin D in muscle fat accumulation and mitochondrial changes.
Original paper ↗Read more →Vitamin D and L-cysteine levels correlate positively with GSH and negatively with insulin resistance levels in the blood of type 2 diabetic patients
Vitamin D, L-cysteine (LC) and glutathione (GSH) levels are lower in the blood of diabetic patients.
Original paper ↗Read more →Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation
Background: The primary objective of the study was to assess serum 25-hydroxyvitamin D [25(OH)D] values in patients with Cushing’s disease (CD), compared to controls.
Original paper ↗Read more →Vitamin D intake is associated with insulin sensitivity in African American, but not European American, women
The objective of this study was to test the hypothesis that dietary vitamin D would be associated with a robust measure of insulin sensitivity in AA and EA women.
Original paper ↗Read more →Original sources
25-Hydroxyvitamin D status does not affect energy metabolism among young, healthy, non-obese adults: a metabolic chamber study
Published in Zhang L, Cai H, Bai X, Xiao W, Cao Z-B, Zhang Y (2024). Frontiers in Endocrinology15:1501818. DOI10.3389/fendo (2024).
Publication details
25-Hydroxyvitamin D status does not affect energy metabolism among young, healthy, non-obese adults: a metabolic chamber study. Zhang L, Cai H, Bai X, Xiao W, Cao Z-B, Zhang Y (2024). Frontiers in Endocrinology15:1501818. DOI10.3389/fendo.2024.1501818; PMID39624819; PMC11608976. DOI: 10.3389/fendo.2024.1501818. PMID: 39624819.
Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells
The purpose of present study is to investigate a role of vitamin D in muscle fat accumulation and mitochondrial changes.
Publication details
Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells. Chang E, Kim Y (2019). Nutrients11(11):2806. DOI10.3390/nu11112806; PMID31744213; PMC6893473. DOI: 10.3390/nu11112806. PMID: 31744213.
Prevailing vitamin D status influences mitochondrial and glycolytic bioenergetics in peripheral blood mononuclear cells obtained from adults
Published in Calton EK, Keane KN, Soares MJ, et al. (2016). Redox Biology10:243 to 250. DOI10.1016/j.redox (2016).
Publication details
Prevailing vitamin D status influences mitochondrial and glycolytic bioenergetics in peripheral blood mononuclear cells obtained from adults. Calton EK, Keane KN, Soares MJ, et al. (2016). Redox Biology10:243 to 250. DOI10.1016/j.redox.2016.10.007; PMID27816874; PMC5097975. DOI: 10.1016/j.redox.2016.10.007. PMID: 27816874.
Insulin-sensitizing effects of vitamin D repletion mediated by adipocyte vitamin D receptor: Studies in humans and mice
Published in Lontchi-Yimagou E, Kang S, Goyal A, et al. (2020). Molecular Metabolism42:101095. DOI10.1016/j.molmet (2020).
Publication details
Insulin-sensitizing effects of vitamin D repletion mediated by adipocyte vitamin D receptor: Studies in humans and mice. Lontchi-Yimagou E, Kang S, Goyal A, et al. (2020). Molecular Metabolism42:101095. DOI10.1016/j.molmet.2020.101095; PMID33045433; PMC7585951. DOI: 10.1016/j.molmet.2020.101095. PMID: 33045433.
Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial
Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial.
Publication details
Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial. Cefalo CMA, Conte C, Sorice GP, et al. (2018). Obesity26(4):651 to 657. DOI10.1002/oby.22132; PMID29504254; PMC6175391. DOI: 10.1002/oby.22132. PMID: 29504254.
Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial
Yet, no trials have examined the effects of vitamin D supplementation on NFκB activity in-vivo in humans.
Publication details
Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial. Mousa A, Naderpoor N, Johnson J, et al. (2017). Scientific Reports7:15154. DOI10.1038/s41598-017-15264-1; PMID29123173; PMC5680306. DOI: 10.1038/s41598-017-15264-1. PMID: 29123173.
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts.
Publication details
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. Vimaleswaran KS, Berry DJ, Lu C, et al. (2013). PLoS Medicine10:e1001383. DOI10.1371/journal.pmed.1001383; PMID23393431; PMC3564800. DOI: 10.1371/journal.pmed.1001383. PMID: 23393431.
Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: a randomized controlled trial
Published in Petchey WG et al.. Nephrology (Carlton) (2013).
Publication details
Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: a randomized controlled trial. Petchey WG et al.. Nephrology (Carlton). 2013;18(1):26-35. DOI: 10.1111/j.1440-1797.2012.01662.x. PMID: 23043683.
Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial
Published in Lemieux P et al.. European Journal of Endocrinology (2019).
Publication details
Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial. Lemieux P et al.. European Journal of Endocrinology. 2019;181(3):287-299. DOI: 10.1530/EJE-19-0156. PMID: 31344685.
Postprandial changes in glucose oxidation and insulin sensitivity in metabolic syndrome: Influence of fibroblast growth factor 21 and vitamin D status
Published in Pathak K et al.. Nutrition (2017).
Publication details
Postprandial changes in glucose oxidation and insulin sensitivity in metabolic syndrome: Influence of fibroblast growth factor 21 and vitamin D status. Pathak K et al.. Nutrition. 2017;37:37-42. DOI: 10.1016/j.nut.2016.12.007. PMID: 28359360. Qualitative abstract-level background only; not a fully appraised primary unit.
Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: a randomized placebo-controlled trial
Published in Mousa A et al.. American Journal of Clinical Nutrition (2017).
Publication details
Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: a randomized placebo-controlled trial. Mousa A et al.. American Journal of Clinical Nutrition. 2017;105(6):1372-1381. DOI: 10.3945/ajcn.117.152736. PMID: 28490514. Qualitative abstract-level background only; not a fully appraised primary unit.
Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis
Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis.
Publication details
Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis. Kang S, Tsai LT, Zhou Y, et al. (2015). Nature Cell Biology17(1):44 to 56. DOI10.1038/ncb3080; PMID25503565; PMC4281178. DOI: 10.1038/ncb3080. PMID: 25503565. Qualitative abstract-level background only; not a fully appraised primary unit.
Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice
Published in Wong KE et al.. Journal of Biological Chemistry (2011).
Publication details
Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. Wong KE et al.. Journal of Biological Chemistry. 2011;286(39):33804-33810. DOI: 10.1074/jbc.M111.257568. PMID: 21840998. Qualitative abstract-level background only; not a fully appraised primary unit.